June 11, 2021
Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.
Through venture philanthropy, the CF Foundation has raised and invested hundreds of millions of dollars to fuel CF-specific drug development programs and encouraged pharmaceutical companies to invest in rare-disease research.
The results of these bold investments have been astonishing. Virtually every approved CF drug available today was made possible with CF Foundation support, including the CFTR modulator Trikafta, which will eventually benefit more than 90 percent of people with CF. However, we will not rest until everyone has a therapy that addresses the underlying cause of their disease. It is also critical to develop new and improved treatments for complications from the disease. With this commitment in mind, the Foundation launched our Path to a Cure, an ambitious research initiative to accelerate treatments for everyone with CF and ultimately deliver a cure. We intend to allocate a half billion dollars to the effort through 2025.
Our research funding has more than doubled over the last six years. Additionally, last year we funded approximately $191 million in laboratory research, preclinical drug development, clinical and real-world research, and high-quality, specialized care and training - more than at any other time in the history of the Foundation.
CF is a complex disease requiring complex care and treatment. Thank you for partnering with the CF Foundation to bring an end to CF. We will not stop until it’s done!